SAB Biotherapeutics nabs $14m Series B
Sioux Falls, South Dakota-based SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has raised $14 million in Series B funding.
Sioux Falls, South Dakota-based SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has raised $14 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination